Teprotumumab: A Review in Thyroid Eye Disease

Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67.

Article  CAS  PubMed  Google Scholar 

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.

Article  PubMed  Google Scholar 

Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281–8.

Article  CAS  PubMed  Google Scholar 

Cockerham KP, Padnick-Silver L, Stuertz N, et al. Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2021;10(4):975–87.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Padnick-Silver L, Francis-Sedlak M, et al. Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocr Pract. 2022;28(9):842–6.

Article  PubMed  Google Scholar 

Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Lond). 2021;35(9):2607–12.

Article  CAS  PubMed  Google Scholar 

Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397–405.

Article  CAS  PubMed  Google Scholar 

Horizon Therapeutics USA Inc. TEPEZZA - teprotumumab injection, powder, lyophilized, for solution: US prescribing information. 2022. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28 Oct 2022.

US Food & Drug Administration. FDA approves first treatment for thyroid eye disease [media release]. 21 Jan 2020. https://www.fda.gov/.

Krieger CC, Sui X, Kahaly GJ, et al. Inhibition of TSH/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease. J Clin Endocrinol Metab. 2022;107(4):e1653–60.

Article  PubMed  Google Scholar 

Fernando R, Caldera O, Smith TJ. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. Proc Natl Acad Sci USA. 2021;118(52):1–10.

Article  Google Scholar 

Xin Y, Xu F, Gao Y, et al. Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease. Clin Pharmacokinet. 2021;60(8):1029–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360–72.

Article  CAS  PubMed  Google Scholar 

Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–52.

Article  CAS  PubMed  Google Scholar 

Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438–49.

Article  PubMed  Google Scholar 

US Food & Drug Administration. Teprotumumab: summary review. 2020. https://www.accessdata.fda.gov/. Accessed 28 Oct 2022.

Ugradar S, Wang Y, Mester T, et al. Improvement of asymmetric thyroid eye disease with teprotumumab. Br J Ophthalmol. 2021;106(6):755–9.

Article  PubMed  Google Scholar 

Jain AP, Gellada N, Ugradar S, et al. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2022;106(2):165–71.

Article  PubMed  Google Scholar 

Ho TC, Maamari RN, Kossler AL, et al. Outcomes of patients with thyroid eye disease partially treated with teprotumumab. Ophthalmic Plast Reconstr Surg. 2022. https://doi.org/10.1097/IOP.0000000000002267.

Article  PubMed  Google Scholar 

Diniz SB, Cohen LM, Roelofs KA, et al. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583–91.

Article  PubMed  Google Scholar 

Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2022;36(8):1553–9.

Article  CAS  PubMed  Google Scholar 

Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 2021;23:101111.

Article  PubMed  PubMed Central  Google Scholar 

Ugradar S, Zimmerman E, Parunakian E, et al. Teprotumumab reduces orbital fat and muscle volume in patients with thyroid eye disease [abstract no. LBSAT238]. In: ENDO. 2022.

Ugradar S, Zimmerman E, Parunakian E, et al. Reversal of Graves’ disease-associated facial volume expansion following teprotumumab therapy [abstract no. LBSAT238]. In: ENDO. 2022.

Ugradar S, Braun J, Wang Y, et al. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open. 2021;9(e3809):1–10.

Google Scholar 

Wang Y, Mester T, Ugradar S, et al. Teprotumumab for the treatment of thyroid eye disease: clinical experience from expanded access program (EAP). Invest Ophthalmol Vis Sci. 2021;62(8):3339 (abstract).

Google Scholar 

Adetunji MO, Nguyen BJ, Meer E, et al. Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2021;62(8):3327 (abstract).

Google Scholar 

Douglas RS, Wang Y, Bruch J, et al. Teprotumumab use in a real-world setting: expanded access program findings. Invest Ophthalmol Vis Sci. 2021;62(8):3345.

Google Scholar 

Belinsky I, Creighton FX Jr, Mahoney N, et al. Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg. 2022;38(1):73–8.

Article  PubMed  Google Scholar 

Smith TJ, Bhattacharya RK, Hsu K, et al. Blood glucose in thryoid eye disease (TED) in patients treated with teprotumumab: clinical trials data [abstract no. PSAT265]. In: ENDO. 2022.

Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep. 2022;15(4): e248335.

Article  PubMed  PubMed Central  Google Scholar 

Sears CM, Azad AD, Amarikwa L, et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1–13.

Article  CAS  PubMed  Google Scholar 

Ashraf DC, Jankovic I, El-Nachef N, et al. New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy. Ophthalmic Plast Reconstr Surg. 2021;37(5):e160–4.

Article  PubMed  Google Scholar 

Safo MB, Silkiss RZ. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am J Ophthalmol Case Rep. 2021;22(101069):1–4.

Google Scholar 

Shah K, Charitou M. A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease. AACE Clin Case Rep. 2022;8(4):148–9.

Article  PubMed  PubMed Central  Google Scholar 

Ugradar S, Qashqai A, Holt RJ, et al. Evaluation of United States thyroid eye disease patients receiving an additional course of teprotumumab treatment over 2 years [abstract and poster]. In: 91st Annual Meeting of the American Thyroid Association. 2022.

US National Institutes of Health. ClinicalTrials.gov identifier NCT04583735. 2022. https://clinicaltrials.gov/. Accessed 28 Oct 2022.

Douglas RS, Dailey R, Subramanian PS, et al. Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol. 2022;140(4):328–35.

Article  PubMed  PubMed Central  Google Scholar 

Douglas RS, Kossler AL, Abrams J, et al. Expert consensus on the use of teprotumumab for the management of thyroid eye disease using a modified-delphi approach. J Neuroophthalmol. 2022;42(3):334–9.

Article  PubMed  PubMed Central  Google Scholar 

Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies. Ophthalmology. 2021;128(11):1627–51.

Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif